Haematologica (Mar 2019)
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
- Sophie Park,
- Olivier Kosmider,
- Frédéric Maloisel,
- Bernard Drenou,
- Nicolas Chapuis,
- Thibaud Lefebvre,
- Zoubida Karim,
- Hervé Puy,
- Anne Sophie Alary,
- Sarah Ducamp,
- Frédérique Verdier,
- Cécile Bouilloux,
- Alice Rousseau,
- Marie-Christine Jacob,
- Agathe Debliquis,
- Agnes Charpentier,
- Emmanuel Gyan,
- Bruno Anglaret,
- Cecile Leyronnas,
- Selim Corm,
- Borhane Slama,
- Stephane Cheze,
- Kamel Laribi,
- Shanti Amé,
- Christian Rose,
- Florence Lachenal,
- Andrea Toma,
- Gian Matteo Pica,
- Martin Carre,
- Frédéric Garban,
- Clara Mariette,
- Jean-Yves Cahn,
- Mathieu Meunier,
- Olivier Herault,
- Pierre Fenaux,
- Orianne Wagner-Ballon,
- Valerie Bardet,
- Francois Dreyfus,
- Michaela Fontenay
Affiliations
- Sophie Park
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Olivier Kosmider
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d’Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
- Frédéric Maloisel
- SOL Hematology, Clinique Saint Anne, Strasbourg
- Bernard Drenou
- Department of Hematology, Hôpital Emile Muller, CH de Mulhouse
- Nicolas Chapuis
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l’Inflammation (CRI) Equipe “Hème, Fer et Pathologies Inflammatoires”, Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
- Thibaud Lefebvre
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
- Zoubida Karim
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l’Inflammation (CRI) Equipe “Hème, Fer et Pathologies Inflammatoires”, Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
- Hervé Puy
- INSERM UMR1149, CNRS 8252 - Centre de Recherche sur l’Inflammation (CRI) Equipe “Hème, Fer et Pathologies Inflammatoires”, Labex GREX, Centre Français des Porphyries - Hôpital Louis Mourier HUPNVS, Paris
- Anne Sophie Alary
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d’Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
- Sarah Ducamp
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
- Frédérique Verdier
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
- Cécile Bouilloux
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Alice Rousseau
- Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris Descartes University
- Marie-Christine Jacob
- Institut de Biologie et Pathologie, Immunology, CHU Grenoble-Alpes, Grenoble
- Agathe Debliquis
- Hematology Laboratory, Mulhouse Hospital
- Agnes Charpentier
- Department of Hematology, Hôpital St Philibert, Lille
- Emmanuel Gyan
- Department of Hematology, CHU de Tours
- Bruno Anglaret
- CH de Valence
- Cecile Leyronnas
- Institut Daniel Hollard, Grenoble
- Selim Corm
- Medipole de Savoie, Challes les Eaux
- Borhane Slama
- Department of Hematology, CH d’Avignon
- Stephane Cheze
- Department of Hematology, CHU Caen
- Kamel Laribi
- Department of Hematology , CH Le Mans
- Shanti Amé
- Department of Hematology, Hôpital Civil, CHU Strasbourg
- Christian Rose
- Department of Hematology, Hôpital Saint Vincent de Paul, Lille
- Florence Lachenal
- Department of Hematology CH Pierre Oudot, Bourgoin-Jallieu
- Andrea Toma
- Department of Hematology, Hôpital Universitaire Henri Mondor, AP-HP, Université Paris 12, Créteil
- Gian Matteo Pica
- Department of Hematology, CH Métropole Savoie, Chambery
- Martin Carre
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Frédéric Garban
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Clara Mariette
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Jean-Yves Cahn
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Mathieu Meunier
- Department of Hematology, CHU Grenoble-Alpes, Grenoble;Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Grenoble
- Olivier Herault
- Laboratoire d’Hématologie, CHU Tours
- Pierre Fenaux
- Department of Hematology, Saint Louis Hospital, AP-HP, Université Paris Diderot
- Orianne Wagner-Ballon
- Département d’Hématologie et Immunologie Biologiques, Hôpital Universitaire Henri Mondor, Creteil
- Valerie Bardet
- Service d’Hématologie Immunologie Transfusion, Hôpitaux Universitaires Paris Ile de France-Ouest, AP-HP
- Francois Dreyfus
- Department of Hematology, Cochin Hospital, Paris V, France
- Michaela Fontenay
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d’Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Institut Cochin, Université Paris Descartes
- DOI
- https://doi.org/10.3324/haematol.2018.203158
- Journal volume & issue
-
Vol. 104,
no. 3
Abstract
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including the flow cytometry RED score, serum growth-differentiation factor-15, and hepcidin levels. Inclusion criteria were no prior treatment with erythropoiesis-stimulating agents, low- or intermediate-1-risk myelodysplastic syndrome according to the International Prognostic Scoring System, and a hemoglobin level 4 (P=0.05) and a hepcidin:ferritin ratio 2000 pg/mL and a hepcidin:ferritin ratio
